Clinical trials: Patients With Type 1 or Type 2 Diabetes
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01545791)
- Testing
- insulin detemir
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 1,037 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Type 1 or Type 2 Diabetic Patients
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia episodes under normal clinical practice for patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487408
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,463 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Pain, Diabetic Neuropathies
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and…
- Trial name
- NCT00375960
- Testing
- V3381
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Vernalis (R&D) Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Diabetic Nephropathy
Effect of Pyridorin in Patients With Diabetic Nephropathy
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
- Trial name
- NCT00320021
- Testing
- Pyridorin (pyridoxamine dihydrochloride)
- Volunteers
- 80 people
- Sponsor
- BioStratum
Diabetes, Diabetes Mellitus, Type 1
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00698269
- Testing
- insulin detemir, biphasic insulin aspart 30, insulin aspart
- Where
- Saudi Arabia
- Volunteers
- 5,926 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
- Trial name
- NCT06046833
- Testing
- FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Samita Garg
Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations
Background: Type 2 diabetes mellitus is a main risk factor for cardiovascular disease and heart failure, in part due to diabetic cardiomyopathy.
- Conditions
- Type 2 Diabetes Mellitus, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Familiar Hypocalcuric Hypercalcemia, Healthy Volunteers
- Trial name
- RISC_7T (NCT02023489)
- Testing
- 1H/ 13C and 31P Magnetic Resonance Spectroscopy, Meal Tolerance Test, Hyperglycemic-hyperinsulinemic clamp
- Where
- Austria
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Type 2 Diabetes
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
- Trial name
- NCT04663282
- Testing
- INS068 injection, Insulin Degludec
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 179 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes, Type 2 Diabetes
Blood Glucose Differences Using CGMs Between the Left and Right Arm in Patients With Diabetes
There are multiple CGMs that are FDA approved. However, there are few studies looking at the variability of measurements between the left and right arm, and none looking at this effect in diabetic patients.
- Trial name
- NCT05849428
- Testing
- Freestyle Libre 3
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of the Pacific
Maturity-onset Diabetes of the Young, Monogenic Diabetes
Identifying Maturity-onset Diabetes of the Young in Emirati Patients
Diabetes Mellitus is a disease that affects nearly 1 in 5 people in United Arab Emirates and is one of leading causes of death and disability.
- Conditions
- Maturity-onset Diabetes of the Young, Monogenic Diabetes, MODY
- Trial name
- NCT05586594
- Testing
- Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)
- Volunteers
- 150 people
- Sponsor
- United Arab Emirates University